Xencor (XNCR) Asset Writedowns and Impairment (2013 - 2025)
Xencor's (XNCR) quarterly Asset Writedowns and Impairment came in at -$8.3 million in Q4 2025, down 629.58% on a QoQ basis from $1.6 million in Q3 2025.
Xencor (XNCR) Asset Writedowns and Impairment (2013 - 2025) Analysis & Trends
Xencor (XNCR) has 13 years of Asset Writedowns and Impairment data on file, last reported at -$8.3 million in Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to -$8.3 million in Q4 2025; TTM through Mar 2026 was -$4.9 million, a 204.74% decrease from a year earlier, with the FY2024 full-year figure at $20.4 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at -$8.3 million, down from $1.6 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for XNCR reached as high as $20.6 million in Q1 2024 and fell as low as -$8.3 million in Q4 2025.
- Historically, Asset Writedowns and Impairment has averaged $1.4 million across 5 years, with a median of $253500.0 in 2021.
- Across the five-year window, Asset Writedowns and Impairment tumbled 694.69% in 2022 and jumped 944.55% in 2025, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $207000.0 in 2021, then tumbled by 694.69% to -$1.2 million in 2022, then soared by 35.26% to -$797000.0 in 2023, then soared by 72.4% to -$220000.0 in 2024, then tumbled by 3667.27% to -$8.3 million in 2025.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were -$8.3 million in Q4 2025, $1.6 million in Q3 2025, and $1.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Xencor | 1.49 Bn | 1.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.29 Mn |
| Dec 31, 2025 | -8.29 Mn |
| Sep 30, 2025 | 1.57 Mn |
| Sep 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 1.86 Mn |
| Jun 30, 2025 | 1.86 Mn |
| Mar 31, 2025 | 4.87 Mn |
| Mar 31, 2025 | 4.87 Mn |
| Jun 30, 2024 | -220,000.00 |
| Jun 30, 2024 | -220,000.00 |
| Mar 31, 2024 | 20.65 Mn |
| Mar 31, 2024 | 20.65 Mn |
| Dec 31, 2023 | -797,000.00 |
| Dec 31, 2023 | -797,000.00 |
| Dec 31, 2022 | -1.23 Mn |
| Dec 31, 2022 | -1.23 Mn |
| Sep 30, 2022 | 300,000.00 |
| Sep 30, 2022 | 300,000.00 |
| Jun 30, 2022 | 700,000.00 |
| Jun 30, 2022 | 700,000.00 |